In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Deciphera Pharmaceuticals Inc (DCPH). The company’s shares closed last Monday at $38.25.
“Median PFS in 2L GIST at approx. 10 months – our prior note incorrectly stated as 6 months. Deciphera’s Phase 3 topline data in 4L/4L+ GIST exceeded our expectations – mPFS of 6.3 months vs 1.0 months with placebo (p5 months (press release HERE). Median OS of 15.1 months vs 6.6 months with placebo provides clear evidence of survival benefits.”
According to TipRanks.com, Roy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -25.2% and a 11.9% success rate. Roy covers the Healthcare sector, focusing on stocks such as Aeglea Biotherapeutics Inc, Adaptimmune Therapeutics, and Neon Therapeutics Inc.
Deciphera Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $48.50.
See today’s analyst top recommended stocks >>
Based on Deciphera Pharmaceuticals Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $25 million and GAAP net loss of $21.46 million. In comparison, last year the company had a GAAP net loss of $21.69 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.